Navigation Links
The Pittsburgh Life Sciences Greenhouse Invests $100,000 in ParentPlus
Date:12/13/2007

PITTSBURGH, Dec. 13 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the organization providing capital investments and customized company formation and business growth services to the region's life sciences enterprises, announced that the PLSG has invested $100,000 in ParentPlus. ParentPlus was formed to commercialize innovative and proprietary human fertility technologies and provide subfertile couples worldwide better odds of fulfilling their dream to start a family. Subfertility affects couples, not individuals, and 75 million couples are impacted world-wide. Of these, only 56% seek treatment and a mere 22 % get treatment.

ParentPlus is positioning its initial product, FertPlus(R), to increase the efficacy of fertility treatments and at the same time provide a lower cost alternative to expensive and highly publicized conventional treatments.

The PLSG's $100,000 investment will help ParentPlus develop FertPlus(R) and conduct a sufficiently-sized medical school study to compare binding of sperm exposed to hPSF with a control. The resulting data will be used to prepare for a pre-trial conference with the Food and Drug Administration (FDA) to obtain clearance to market. After clearance by the FDA, FPSPM can be introduced to fertility clinics as the medium used in sperm preparation for IntraUterine Insemination (IUI) treatment.

"Currently there is no other treatment available to enhance the success of IUI," said John W. Manzetti, President & CEO of the PLSG. "The ParentPlus technology will provide couples with a reduced number of insemination attempts, which helps alleviate the financial and emotional stress associated with subfertility." Mr. Manzetti continued, "There are currently no FDA- approved pro-fertility products acting on human sperm. The development and success of ParentPlus' product will be the first such medium with significant potential to increase the probability of couples becoming pregnant and can ultimately
'/>"/>

SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
2. The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio
3. The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
4. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com announces ... available in its catalogue: ,, Carbondioxide ... ,, http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators ... microbiology, genetics, cancer, research, and other applications ...
(Date:12/2/2009)... Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ... previously announced unit offering, the underwriters have exercised in ... units. Each unit is comprised of one common share ... was sold at a price of US$3.00 per unit. ...
(Date:12/2/2009)... today announced data presentations on its novel oral JAK2 ... Annual Meeting and Exposition in New Orleans. ,, Data ... Phase 1 dose-escalation trial of SB1518 detailing its safety, ... from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)... The Scientist, a leading scientific magazine covering the life sciences, ... “Top 10 Innovations of 2009. , ... ... EMCCD camera from Photometrics ®, a designer and ...
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
... April 23 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, today announced very strong,participation in ... the Company,s,Visian ICL(TM) (Implantable Collamer Lens). The first ... My Website Compels Patients to Call,Me," is part ...
... Pipeline of Oncology Products Including Novel Nucleoside Analogue; New ... ... MacroChem Corporation (OTC,Bulletin Board: MACM) announced today that on April ... company,developing and commercializing novel therapeutics, with a portfolio of,clinical stage ...
... patients treated with PBI-1402 did not require blood ... ... ProMetic Life Sciences Inc.,(TSX: PLI) ("ProMetic") announces that oral PBI-1402 demonstrates,significant ... red blood cell ("RBC") transfusion., Only 2 patients out of ...
Other Biology Technology:More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 2More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 3MacroChem Acquires Virium Pharmaceuticals 2MacroChem Acquires Virium Pharmaceuticals 3MacroChem Acquires Virium Pharmaceuticals 4MacroChem Acquires Virium Pharmaceuticals 5Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial 2Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial 3
(Date:12/4/2009)... Dr. Daniel Leskovar, a Texas AgriLife Research plant ... in Uvalde, has been investigating ways to help vegetable ... to the field. , "This research can aid in ... of some vegetable crops by producing high-quality, more adaptive ...
(Date:12/4/2009)... widely used by physicians and scientists to study brain ... remained largely unknown whether the electrodes on the head ... the brain. Scientists at the Max Planck Institute for ... crucial link between the activity generated within the brain ...
(Date:12/3/2009)... 3 BIO-key International, Inc. (OTC Bulletin Board: ... finger-based biometric identification solutions, announced that a majority ... held today approved the sale of the company,s ... Of the shares voted, 98.6% were cast in ...
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How to read brain activity? 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Council for American Medical Innovation to Host Capitol Hill Breakfast Briefing on Education and Immigration 3A The Building Blocks of Innovation 56116 1Council for American Medical Innovation to Host Capitol Hill Breakfast Briefing on Education and Immigration 3A The Building Blocks of Innovation 56116 2The Power of Five 3A New OmniFlex Nourishes Joints in Convenient Effective Doses 56112 1The Power of Five 3A New OmniFlex Nourishes Joints in Convenient Effective Doses 56112 2Arena Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Global Investment Conference 13817 1Arena Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Global Investment Conference 13817 2Arena Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Global Investment Conference 13817 3
... trees -- some are short and bushy with many branches ... of one or two main trunks. Different branching patterns correlate ... these dissimilar patterns come about and why. , A new ... University of New Jersey, examines the role of the protein ...
... gene expression in the brain can differ significantly among ... study indicates that roughly 15 percent of Atlantic salmon ... their freshwater birthplaces to mature in oceans versus those ... , The researchers, at Harvard University, the University of ...
... biological trigger that gives rise to Van Buchem ... cause blindness and deafness. The findings provide insight ... new treatments for osteoporosis and other crippling bone ... and Lawrence Berkeley national laboratories, the Novartis Institutes ...
Other Biology News:Snapin: A protein with therapy potential for autism 2Divergent life history shapes gene expression in brains of salmon 2Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3
... For the efficient enrichment of functional ... or cell culture. The isolated ER ... and metabolic pathway analysis. Metabolic abnornalities ... in children, cystic fibrosis and many ...
Plasmid expressing PLAP reporter gene....
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: